Table 1 Relationship between expression of SOX9 and clinicopathologic characteristics of breast cancer patients.

Variables	Sox9 low (135)		Sox9 high (143)		P-value
Variables	No.	%	No.	%	P-value
Age					0.474
<53 years	70	51.85%	68	47.55%
≥53 years	65	48.15%	75	52.45%
Pathology grade^a					0.014
Grade 1	22	16.42%	11	7.69%
Grade 2	95	70.90%	99	69.23%
Grade 3	17	12.69%	33	23.08%
T stage^b					0.038
1	40	30.08%	46	32.17%
2	92	69.17%	88	61.54%
3	1	0.75%	9	6.29%
Nodal status^c					0.748
Negative	56	44.09%	62	45.58%
1–3 positive nodes	35	27.56%	36	26.47%
4–9 positive nodes	31	24.40%	29	21.32%
≥10 positive nodes	5	3.94%	9	6.62%
ER status^d					<0.0001
Positive	103	81.75%	71	50.35%
Negative	23	18.25%	70	49.65%
PR status^e					<0.0001
Positive	88	68.75%	60	42.55%
Negative	40	31.25%	81	57.45%
Her2 status^f					0.525
Positive	29	24.17%	36	27.69%
Negative	91	75.83%	94	72.31%
Outcome^g					0.085
Death	29	21.64%	44	30.77%
Survival	105	78.36%	99	69.23%
Subtypes^h
Luminal A	75	64.1%	57	40.43%	0.001
Luminal B	20	17.09%	22	15.60%
HER2-positive	6	5.13%	20	14.18%
TNBC	16	13.68%	42	29.79%

^a1 sample of pathology grade status of Sox9 low expression group was missed.
^b2 samples of T stage status of Sox9 low and high expression group were missed, respectively.
^c8 and 7 samples of nodal status of Sox9 low and high expression group were missed, respectively.
^d7 and 2 samples of ER status of Sox9 low and high expression group were missed, respectively.
^e7 and 2 samples of PR status of Sox9 low and high expression group were missed, respectively.
^f15 and 13 samples of HER2 status of Sox9 low and high expression group were missed, respectively.
^g1 sample of outcome status of Sox9 low expression group was missed, respectively.
^h18 and 2 samples of subtype status of Sox9 low and high expression group were missed, respectively.

Quick links

Search